LMR Partners LLP acquired a new stake in bluebird bio, Inc. (NASDAQ:BLUE) during the second quarter, Holdings Channel reports. The institutional investor acquired 35,726 shares of the biotechnology company’s stock, valued at approximately $3,753,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of BLUE. FMR LLC increased its position in bluebird bio by 0.6% in the first quarter. FMR LLC now owns 6,126,713 shares of the biotechnology company’s stock valued at $556,918,000 after buying an additional 37,742 shares during the last quarter. Baillie Gifford & Co. increased its position in bluebird bio by 0.8% in the first quarter. Baillie Gifford & Co. now owns 5,204,633 shares of the biotechnology company’s stock valued at $473,102,000 after buying an additional 40,166 shares during the last quarter. Vanguard Group Inc. increased its position in bluebird bio by 4.6% in the first quarter. Vanguard Group Inc. now owns 3,215,246 shares of the biotechnology company’s stock valued at $292,266,000 after buying an additional 141,293 shares during the last quarter. BlackRock Inc. increased its position in bluebird bio by 44,948.0% in the first quarter. BlackRock Inc. now owns 3,182,188 shares of the biotechnology company’s stock valued at $289,259,000 after buying an additional 3,175,124 shares during the last quarter. Finally, State Street Corp increased its position in bluebird bio by 3.7% in the first quarter. State Street Corp now owns 1,611,032 shares of the biotechnology company’s stock valued at $146,443,000 after buying an additional 58,228 shares during the last quarter.

bluebird bio, Inc. (NASDAQ BLUE) opened at 96.60 on Tuesday. The stock has a 50 day moving average of $98.08 and a 200 day moving average of $90.65. The company’s market capitalization is $4.40 billion. bluebird bio, Inc. has a 12 month low of $37.05 and a 12 month high of $123.75.

bluebird bio (NASDAQ:BLUE) last issued its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.73) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.66) by $0.07. The company had revenue of $16.70 million during the quarter, compared to analysts’ expectations of $6.29 million. bluebird bio had a negative return on equity of 32.19% and a negative net margin of 1,080.59%. bluebird bio’s quarterly revenue was up 977.4% compared to the same quarter last year. During the same period last year, the firm posted ($1.59) earnings per share. Equities analysts anticipate that bluebird bio, Inc. will post ($6.78) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This article was posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright law. The correct version of this article can be viewed at https://www.watchlistnews.com/lmr-partners-llp-invests-3-75-million-in-bluebird-bio-inc-blue/1490504.html.

Several research analysts have recently issued reports on BLUE shares. Zacks Investment Research downgraded shares of bluebird bio from a “hold” rating to a “sell” rating in a report on Tuesday, April 25th. BTIG Research lowered shares of bluebird bio from a “buy” rating to a “neutral” rating and lifted their target price for the company from $37.05 to $108.25 in a research report on Friday, June 30th. Wedbush reiterated an “outperform” rating and set a $100.00 target price (down from $121.00) on shares of bluebird bio in a research report on Friday, June 23rd. Cowen and Company reiterated an “outperform” rating on shares of bluebird bio in a research report on Friday, June 9th. Finally, BidaskClub upgraded shares of bluebird bio from a “sell” rating to a “hold” rating in a research report on Wednesday, August 9th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and eleven have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $100.66.

In other news, Director Daniel Lynch sold 2,000 shares of the company’s stock in a transaction dated Thursday, May 25th. The stock was sold at an average price of $80.00, for a total transaction of $160,000.00. Following the sale, the director now directly owns 3,400 shares in the company, valued at $272,000. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Nick Leschly sold 25,000 shares of the company’s stock in a transaction dated Tuesday, June 27th. The shares were sold at an average price of $108.05, for a total value of $2,701,250.00. Following the sale, the insider now owns 360,656 shares in the company, valued at $38,968,880.80. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 79,106 shares of company stock worth $8,212,408. Insiders own 3.90% of the company’s stock.

bluebird bio Company Profile

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Want to see what other hedge funds are holding BLUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for bluebird bio, Inc. (NASDAQ:BLUE).

Institutional Ownership by Quarter for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.